Literature DB >> 15828847

Potent and selective Aurora inhibitors identified by the expansion of a novel scaffold for protein kinase inhibition.

Daniele Fancelli1, Daniela Berta, Simona Bindi, Alexander Cameron, Paolo Cappella, Patrizia Carpinelli, Cornel Catana, Barbara Forte, Patrizia Giordano, Maria Laura Giorgini, Sergio Mantegani, Aurelio Marsiglio, Maurizio Meroni, Juergen Moll, Valeria Pittalà, Fulvia Roletto, Dino Severino, Chiara Soncini, Paola Storici, Roberto Tonani, Mario Varasi, Anna Vulpetti, Paola Vianello.   

Abstract

Potent and selective Aurora kinase inhibitors were identified from the combinatorial expansion of the 1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole bi-cycle, a novel and versatile scaffold designed to target the ATP pocket of protein kinases. The most potent compound reported in this study had an IC(50) of 0.027 microM in the enzymatic assay for Aur-A inhibition and IC(50)s between 0.05 microM and 0.5 microM for the inhibition of proliferation of different tumor cell lines.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15828847     DOI: 10.1021/jm049076m

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  29 in total

Review 1.  Aurora kinase inhibitors as anticancer molecules.

Authors:  Hiroshi Katayama; Subrata Sen
Journal:  Biochim Biophys Acta       Date:  2010-09-20

2.  MLN8054, a small-molecule inhibitor of Aurora A, causes spindle pole and chromosome congression defects leading to aneuploidy.

Authors:  Kara Hoar; Arijit Chakravarty; Claudia Rabino; Deborah Wysong; Douglas Bowman; Natalie Roy; Jeffrey A Ecsedy
Journal:  Mol Cell Biol       Date:  2007-04-16       Impact factor: 4.272

3.  Structural studies of B-type Aurora kinase inhibitors using computational methods.

Authors:  Mm Neaz; M Muddassar; Fa Pasha; Seung Joo Cho
Journal:  Acta Pharmacol Sin       Date:  2010-02       Impact factor: 6.150

4.  Development of o-chlorophenyl substituted pyrimidines as exceptionally potent aurora kinase inhibitors.

Authors:  Matthew P Martin; Yunting Luo; Roberta Pireddu; Hua Yang; Harsukh Gevariya; Harshani R Lawrence; Sevil Ozcan; Jin-Yi Zhu; Robert Kendig; Mercedes Rodriguez; Roy Elias; Jin Q Cheng; Saïd M Sebti; Ernst Schonbrunn; Nicholas J Lawrence
Journal:  J Med Chem       Date:  2012-08-30       Impact factor: 7.446

5.  Kinome chemoproteomics characterization of pyrrolo[3,4-c]pyrazoles as potent and selective inhibitors of glycogen synthase kinase 3.

Authors:  Martin Golkowski; Gayani K Perera; Venkata Narayana Vidadala; Kayode K Ojo; Wesley C Van Voorhis; Dustin J Maly; Shao-En Ong
Journal:  Mol Omics       Date:  2018-02-12

6.  Preclinical characterization of Aurora kinase inhibitor R763/AS703569 identified through an image-based phenotypic screen.

Authors:  John McLaughlin; Vadim Markovtsov; Hui Li; Steve Wong; Marina Gelman; Yanhong Zhu; Christian Franci; D Wayne Lang; Erlina Pali; Joe Lasaga; Caroline Low; Feifei Zhao; Betty Chang; Tarikere L Gururaja; Weiduan Xu; Muhammad Baluom; David Sweeny; David Carroll; Arvinder Sran; Sambaiah Thota; Manjeet Parmer; Angela Romane; George Clemens; Elliott Grossbard; Kunbin Qu; Yonchu Jenkins; Taisei Kinoshita; Vanessa Taylor; Sacha J Holland; Ankush Argade; Rajinder Singh; Polly Pine; Donald G Payan; Yasumichi Hitoshi
Journal:  J Cancer Res Clin Oncol       Date:  2010-01       Impact factor: 4.553

7.  tert-Butyl 3-amino-2-methyl-6,7-dihydro-2H-pyrazolo[4,3-c]pyridine-5(4H)-carboxyl-ate.

Authors:  Xin Guo; Xiao Guang Bai; Yi Liang Li; Yu Cheng Wang
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2010-04-17

8.  In vitro selection of a DNA-templated small-molecule library reveals a class of macrocyclic kinase inhibitors.

Authors:  Ralph E Kleiner; Christoph E Dumelin; Gerald C Tiu; Kaori Sakurai; David R Liu
Journal:  J Am Chem Soc       Date:  2010-08-25       Impact factor: 15.419

9.  4-(2-Oxa-6-aza-spiro-[3.3]hept-6-yl)-benzo-nitrile.

Authors:  Jian Li; Ting Xu; Peng-Bo Wu; Jing Lu; Yao Tang
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2010-04-28

10.  The human Aurora kinase inhibitor danusertib is a lead compound for anti-trypanosomal drug discovery via target repurposing.

Authors:  Stefan O Ochiana; Vidya Pandarinath; Zhouxi Wang; Rishika Kapoor; Mary Jo Ondrechen; Larry Ruben; Michael P Pollastri
Journal:  Eur J Med Chem       Date:  2012-07-31       Impact factor: 6.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.